Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection?: Commentary on the meta-analysis by Bongartz et al.

被引：34

作者：

Dixon, Will ^{[1
]}

Silman, Alan ^{[1
]}

机构：

[1] Univ Manchester, Sch Med, Epidemiol Unit, Manchester, Lancs, England

来源：

ARTHRITIS RESEARCH & THERAPY | 2006年 / 8卷 / 05期

关键词：

D O I：

10.1186/ar2026

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A recent meta-analysis of randomized clinical trials reported by Bongartz and coworkers raised concerns about an increased rate of malignancy and serious infection in rheumatoid arthritis patients treated with anti-tumour necrosis factor monoclonal antibodies. This commentary discusses some of the methodological issues in their analysis and urges caution in interpreting the results.

引用

页数：3

共 8 条

[1] Haematopoietic malignancies in rheumatoid arthritis:: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists [J].

Askling, J ;

Fored, CM ;

Baecklund, E ;

Brandt, L ;

Backlin, C ;

Ekbom, A ;

Sundström, C ;

Bertilsson, L ;

Cöster, L ;

Geborek, P ;

Jacobsson, LT ;

Lindblad, S ;

Lysholm, J ;

Rantapää-Dahlqvist, S ;

Saxne, T ;

Klareskog, L ;

Feltelius, N .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1414-1420

[2] Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis [J].

Baecklund, E ;

Iliadou, A ;

Askling, J ;

Ekborn, A ;

Backlin, C ;

Granath, F ;

Catrina, AT ;

Rosenquist, R ;

Feltelius, N ;

Sundström, C ;

Klareskog, L .

ARTHRITIS AND RHEUMATISM, 2006, 54 (03) :692-701

[3] Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].

Bongartz, T ;

Sutton, AJ ;

Sweeting, MJ ;

Buchan, I ;

Matteson, EL ;

Montori, V .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285

[4] Tumor necrosis factor antagonist therapy and lymphoma development - Twenty-six cases reported to the Food and Drug Administration [J].

Brown, SL ;

Greene, MH ;

Gershon, SK ;

Edwards, ET ;

Braun, MM .

ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3151-3158

[5] Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy - Results from the British Society for Rheumatology Biologics Register [J].

Dixon, W. G. ;

Watson, K. ;

Lunt, M. ;

Hyrich, K. L. ;

Silman, A. J. ;

Symmons, D. P. M. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (08) :2368-2376

[6] Infections in patients with rheumatoid arthritis treated with biologic agents [J].

Listing, J ;

Strangfeld, A ;

Kary, S ;

Rau, R ;

von Hinueber, U ;

Stoyanova-Scholz, M ;

Gromnica-Ihle, E ;

Antoni, C ;

Herzer, P ;

Kekow, J ;

Schneider, M ;

Zink, A .

ARTHRITIS AND RHEUMATISM, 2005, 52 (11) :3403-3412

[7] Anti-tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis:: No clear answer [J].

Symmons, DPM ;

Silman, AJ .

ARTHRITIS AND RHEUMATISM, 2004, 50 (06) :1703-1706

[8] Lymphoma in rheumatoid arthritis - The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients [J].

Wolfe, F ;

Michaud, K .

ARTHRITIS AND RHEUMATISM, 2004, 50 (06) :1740-1751

← 1 →